Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, although it is not a cure and requires weight loss to be maintained over time.

New York Attorney General Letitia James on Friday released what she described as “shocking and disturbing” footage from body-worn cameras of correctional officers showing the fatal beating of an inmate at the Marcy Correctional Facility in upstate New York.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP machines remain the first-line treatment.

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as tirzepatide, to help people treat obstructive sleep apnea.

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.